Transition of antibody titers after the SARS-CoV-2 mRNA vaccine in Japanese healthcare workers
Transition of antibody titers after the SARS-CoV-2 mRNA vaccine in Japanese healthcare workers
复制标题
日本医护人员接种 SARS-CoV-2 mRNA 疫苗后抗体滴度的变化
DOI：
10.1101/2021.12.28.21268435
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Mat
中科院分区：
文献类型：
--
作者：
Kitabatake Masahiro;Ouji-Sageshima Noriko;Sonobe Shota;Furukawa Ryutaro;Konda Makiko;Hara Atsushi;Aoki Hiroyasu;Suzuki Yuki;Imakita Natsuko;Nakano Akiyo;Fujita Yukio;Shichino Shigeyuki;Nakano Ryuichi;Ueha Satoshi;Kasahara Kei;Muro Shigeo;Yano Hisakazu;Mat
自2021年2月起，日本的医护人员优先接种了针对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的信使RNA疫苗（BNT 162 b2/辉瑞）。虽然许多研究已经证实这种疫苗在减少2019冠状病毒病（COVID-19）的住院和死亡方面非常有效，但抗体滴度往往在3个月时下降，导致突破性感染的风险。因此，需要信息来支持关于第三次疫苗接种的决策。在这项研究中，我们调查了41名接种疫苗的日本医护人员的抗SARS-CoV-2受体结合域（RBD）IgG和中和抗体滴度的变化。从接种前1周开始至接种后6个月，采集7次样本。抗SARS-CoV-2 RBD IgG水平在加强后7天达到峰值，然后随时间下降，并在加强后6个月下降至<10%。抗SARS-CoV-2 RBD IgG水平低的工人也有低中和抗体滴度。这些数据支持医护人员积极使用加强剂，特别是对于那些抗SARS-CoV-2 RBD IgG水平低的人。
Since February 2021, health care workers in Japan have been preferentially vaccinated with a messenger RNA vaccine (BNT162b2/Pfizer) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While many studies have confirmed that this vaccine is highly effective in reducing hospitalizations and deaths from coronavirus disease 2019 (COVID-19), antibody titers tend to decline at 3 months, leading to a risk of breakthrough infections. Thus, information is needed to support decision making regarding the third vaccination. In this study, we investigated transition of the anti-SARS-CoV-2 receptor-binding domain (RBD) IgG and neutralizing antibody titers of 41 vaccinated Japanese healthcare workers. Samples were collected seven times starting 1 week before vaccination until 6 months post-vaccination. Anti-SARS-CoV-2 RBD IgG levels peaked at 7 days after the booster, then declined over time and decreased to <10% at 6 months after the booster. Workers with low anti-SARS-CoV-2 RBD IgG levels also had low neutralizing antibody titers. These data support the active use of boosters for healthcare workers, especially for those with low anti-SARS-CoV-2 RBD IgG levels.